Sun Pharmaceutical Industries, India's top drugmaker offered to buy all of the outstanding shares it does not already own in its Israeli unit Taro Pharmaceutical Industries. The drug maker proposed to buy per share at a consideration of $24.50 in cash representing a 25.96% premium over the most recent price of Taro common stock.
Further, this offer is subject to the approval of Taro board and such other authorities as may be required and subject to completion of necessary formalities as may be required.
Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1874.00 |
| Dr. Reddys Lab | 1295.00 |
| Cipla | 1321.95 |
| Zydus Lifesciences | 946.80 |
| Lupin | 2271.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: